Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 May;15(4):559-71.
doi: 10.1017/S146114571100037X. Epub 2011 Mar 14.

The ethics of elective psychopharmacology

Ahmed D Mohamed  1 , Barbara J Sahakian
Affiliations
Free PMC article
Review

The ethics of elective psychopharmacology

Ahmed D Mohamed et al. Int J Neuropsychopharmacol. 2012 May.
Free PMC article

Abstract

Pharmacological cognitive enhancers (PCEs) are used to improve cognitive functions, such as attention, learning, memory and planning in patients with impairments in cognition resulting from traumatic brain injury (TBI) or from neuropsychiatric disorders such as Alzheimer's disease (AD), mild cognitive impairment, schizophrenia, and attention deficit hyperactivity disorder (ADHD). Moreover, PCEs have been shown to improve cognition in healthy volunteers with no psychiatric disorders. This article describes the rationale behind the need for their use in neuropsychiatric patients and illustrates how PCEs can ameliorate cognitive impairments, improve quality of life and wellbeing, and therefore reduce the economic burden associated with these disorders. We also describe evidence that PCEs are being used as cognitive enhancers by healthy people. Crucially, as the lifestyle use of these drugs becomes very popular in the healthy population, a final aim is to present an overview of the current and future neuroethical considerations of enhancing the healthy brain. As information regarding their actual use, benefits and harms in various healthy populations is currently lacking, we propose research that aims to obtain relevant empirical data, monitor the short- and long-term effectiveness and side-effects, and initiate accurate surveys to determine current patterns and quantity of usage of PCE drugs by healthy people. Furthermore, in order to instigate a dialogue between neuroethics and neuropsychopharmacology, we urge scientists to explore and communicate the social and ethical implications of their research to the public. Finally, we discuss and highlight other means of enhancing cognition in both patients and healthy adults, including education and physical exercise.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Academy of Medical Sciences. Brain Science, Addiction and Drugs: Working Group Report Chaired by Professor Sir Gabriel Horn. Foresight Brain Science, Addiction and Drugs Project. London: Office of Science and Technology; 2008.
    1. Ajibola O, Clement PW. Differential effects of methylphenidate and self-reinforcement on attention-deficit hyperactivity disorder. Behavior Modification. 1995;19:211–233. - PubMed
    1. Altamura AC, Glick ID. Designing outcome studies to determine efficacy and safety of antipsychotics for ‘real world’ treatment of schizophrenia: trends and Perspectives. International Journal of Neuropsychopharmacology. 2010;13:971–973. - PubMed
    1. Alzheimer's Association. 2005. http://www.alz.org/national/documents/topicsheet_treatments.pdf. http://www.alz.org/national/documents/topicsheet_treatments.pdf ). FDA-approved treatments for Alzheimer's ( ). Accessed November 2010.
    1. Alzheimer's Research Trust. Dementia 2010: the economic burden of dementia and associated research funding in the United Kingdom. Health Economics Research Centre. Alzheimer's Research Trust; 2010. pp. 1–38.

Publication types

Substances